KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts

Intern Med. 1998 Mar;37(3):307-10. doi: 10.2169/internalmedicine.37.307.

Abstract

KL-6, a serum marker for interstitial pneumonitis, was evaluated in patients with Pneumocystis carinii pneumonia (PCP). Patient 1 was a 56-year-old woman with rheumatoid arthritis treated with immunosuppressive drugs and corticosteroids. Patient 2 was a 59-year-old man with a glioblastoma who received anti-cancer drugs and corticosteroids. In both patients, serum KL-6 showed an abnormally high level due to the complication of PCP, and it decreased following successful treatment. These results indicate that PCP is one of the diseases in which serum KL-6 increases.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens
  • Antigens, Neoplasm
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Biomarkers / blood*
  • Biopsy
  • Brain Neoplasms / complications
  • Brain Neoplasms / drug therapy
  • Female
  • Follow-Up Studies
  • Glioblastoma / complications
  • Glioblastoma / drug therapy
  • Glycoproteins
  • Humans
  • Immunocompromised Host*
  • Immunohistochemistry
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Mucin-1
  • Mucins / blood*
  • Peptide Fragments / blood*
  • Pneumonia, Pneumocystis / blood*
  • Pneumonia, Pneumocystis / complications
  • Pneumonia, Pneumocystis / pathology
  • Procollagen / blood*

Substances

  • Antigens
  • Antigens, Neoplasm
  • Biomarkers
  • Glycoproteins
  • Immunosuppressive Agents
  • MUC1 protein, human
  • Mucin-1
  • Mucins
  • Peptide Fragments
  • Procollagen
  • procollagen Type III-N-terminal peptide